A5078780201- RNA Interference and Gene Delivery
- MicroRNA in disease regulation
- Advanced biosensing and bioanalysis techniques
- Ferroptosis and cancer prognosis
- Nanoplatforms for cancer theranostics
- Virus-based gene therapy research
- Cancer, Lipids, and Metabolism
- Nanoparticle-Based Drug Delivery
- Monoclonal and Polyclonal Antibodies Research
Tianjin Medical University
2021-2024
Intrinsic or acquired resistance to chemical drugs severely limits their therapeutic efficacy in cancer treatment. Various intracellular antioxidant molecules, particularly glutathione (GSH), play a crucial role maintaining redox homeostasis by mitigating the overproduced reactive oxygen species (ROS) due rapid cell proliferation. Notably, these antioxidants also eliminate chemical-drug-induced ROS, eventually diminishing cytotoxicity and rendering them less effective. In this study, we...
Antibody–drug conjugates (ADC) utilizing the targeting properties of antibodies and therapeutic effects drugs have emerged a rapid development in recent years. However, relatively low drug loading capacity ADC systems commonly results failure delivering enough chemical to desired areas given safe antibody dose, therefore efficacy is restricted. With FDA approval four siRNA drugs, patisiran, givosiran, lumasiran inclisiran, siRNAs has regained huge attention researchers, where design delivery...